Welcome to our dedicated page for Inhibikase Therapeutics SEC filings (Ticker: IKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Inhibikase Therapeutics, Inc. (Nasdaq: IKT) SEC filings page on Stock Titan provides access to the company’s publicly filed regulatory documents, including current reports on Form 8-K and other submissions made through the U.S. Securities and Exchange Commission’s EDGAR system. As a clinical-stage pharmaceutical company developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease, Inhibikase uses these filings to report material corporate events, financing transactions, governance matters, and key developments in its pulmonary arterial hypertension (PAH) program.
Inhibikase’s recent 8-K filings describe, among other items, the entry into an underwriting agreement for a public offering of common stock and pre-funded warrants, the expected net proceeds from that offering, and amendments to outstanding warrants in connection with plans to advance IKT-001 to a global pivotal Phase 3 study in PAH. Other 8-Ks report financial results for specific periods, updates to corporate presentations, and outcomes of the company’s annual meeting of stockholders, including director elections, auditor ratification, and equity incentive plan amendments.
Through this page, users can review how Inhibikase discloses its clinical development strategy for IKT-001, including the planned two-part adaptive Phase 3 IMPROVE-PAH study, as well as its capital-raising activities that support ongoing research and development. Stock Titan enhances these filings with AI-powered summaries that explain the core points of lengthy documents such as current reports, shelf registration statements, and related exhibits. Investors can also monitor information related to equity offerings, warrant terms, and other securities matters that may affect the company’s capital structure.
By consolidating Inhibikase’s SEC filings and applying AI-driven analysis, this page helps readers quickly understand the regulatory and financial context surrounding the company’s PAH-focused clinical programs and broader corporate activities.
Inhibikase Therapeutics filed an 8-K to share news that the first patient has been enrolled in its pivotal global Phase 3 IMPROVE-PAH study of IKT-001 for Pulmonary Arterial Hypertension (PAH). This marks a key step in moving the program into late-stage testing.
IKT-001 is a novel oral prodrug of imatinib mesylate, designed to lessen gastrointestinal side effects associated with imatinib. The IMPROVE-PAH trial uses a two-part adaptive Phase 3 design with a 12-week dose‑titration phase to help patients reach the highest tolerable dose.
Part A will enroll approximately 140 patients and measure change in pulmonary vascular resistance at Week 24. Part B will follow seamlessly, enrolling about 346 patients and focusing on change in 6-minute walk distance at Week 24. The study may include up to roughly 180 sites worldwide and allows for sample size re-estimation for Part B based on Part A findings. Inhibikase describes PAH as a progressive, life‑threatening disease affecting about 50,000 Americans and views this single pivotal Phase 3 trial as central to advancing IKT-001 toward potential regulatory review.
Inhibikase Therapeutics provides an annual update focused on its lead oral prodrug, IKT-001, being advanced as a potential disease‑modifying treatment for pulmonary arterial hypertension (PAH). The company has shifted strategic focus to PAH and initiated an adaptive global Phase 3 trial, IMPROVE‑PAH, in two parts across approximately 180 sites.
The filing describes prior bioequivalence work showing IKT‑001 doses that match imatinib exposure, FDA feedback supporting the 505(b)(2) pathway, and plans to seek Orphan Drug Designation. Inhibikase reports global commercialization rights and patent coverage for IKT‑001 extending, if granted and maintained, into a 2033–2045 window.
Recent corporate actions include pausing risvodetinib development, acquiring CorHepta Pharmaceuticals in an all‑stock transaction valued at $15.0 million, and licensing risvodetinib to ABLi Therapeutics with potential development and regulatory milestones up to $47.5 million plus double‑digit royalties. The company also raised $115,000,000 in gross proceeds via a public equity and pre‑funded warrant offering and maintains additional flexibility through a Form S‑3 shelf and at‑the‑market program. Context figures include a reported aggregate non‑affiliate market value of common stock of $127.3 million as of June 30, 2025, and 132,032,636 shares outstanding as of March 20, 2026.
Inhibikase Therapeutics reported a larger net loss for 2025 as it advanced its lead Pulmonary Arterial Hypertension program into a global pivotal Phase 3 trial called IMPROVE-PAH. Net loss was $48.3 million, or $0.49 per share, compared with $27.5 million, or $1.16 per share in 2024.
Research and development expenses rose to $29.8 million, including a $7.4 million non-cash write-off of in-process R&D and $2.5 million of stock-based compensation tied to the February 2025 CorHepta acquisition. Selling, general and administrative expenses increased to $23.6 million, including $1.0 million of severance from senior executive transitions.
Cash, cash equivalents and marketable securities were $178.8 million as of December 31, 2025, up from $97.5 million a year earlier, supported by $107.6 million of net proceeds from issuing common stock, pre-funded warrants and warrants. The company highlighted ongoing regulatory submissions in more than 20 countries and active enrollment in its single pivotal Phase 3 PAH study.
Inhibikase Therapeutics director Vincent Aurentz forfeited 255,299 shares of common stock back to the company. These shares had been received as part of the CorHepta Pharmaceuticals acquisition and were subject to forfeiture if a milestone was not met by the first anniversary of the February 21, 2025 closing date.
On February 21, 2026, the milestone was determined not to have been achieved, triggering the return of all 255,299 shares to the issuer at no cost. After this issuer disposition, Aurentz directly holds 510,596 shares of Inhibikase Therapeutics common stock.
Inhibikase Therapeutics executive Cabell Christopher reported the forfeiture of 338,282 shares of common stock back to the company. These shares had been received as part of the CorHepta Pharmaceuticals acquisition completed on February 21, 2025, but were subject to a milestone that had to be met by the first anniversary of that closing date.
On February 21, 2026, the milestone was determined not to have been achieved, causing all 338,282 shares to be returned to the issuer for no consideration. Following this disposition to the issuer, Christopher directly holds 676,564 shares of Inhibikase common stock.
Inhibikase Therapeutics director Amit Munshi reported a forfeiture of previously issued shares. On February 21, 2026, 19,089 shares of common stock were returned to the company after a milestone related to the February 21, 2025 CorHepta Pharmaceuticals acquisition was not achieved. Munshi received no cash or other consideration for this disposition to the issuer.
Following the forfeiture, he holds 38,176 shares of common stock directly and 365,000 shares indirectly through the Amit Munshi Revocable Trust.
Inhibikase Therapeutics, Inc. attracted a significant institutional holder, with ADAR1-affiliated entities reporting beneficial ownership of 9.9% of its common stock. ADAR1 Capital Management, ADAR1 Capital Management GP and manager Daniel Schneeberger report shared voting and dispositive power over between 12.5 million and 12.7 million shares, including milestone warrant shares.
The holdings span limited partnerships, a Spearhead Insurance vehicle and separately managed accounts, with additional milestone warrants contractually limited by a 9.99% beneficial ownership cap. Ownership percentages are based on 120,899,650 Inhibikase common shares outstanding as of November 24, 2025.
Inhibikase Therapeutics, Inc. received an amended Schedule 13G/A showing that Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., and principals Peter Harwin and Tomas Kiselak collectively report beneficial ownership of 12,461,101 shares of Common Stock, representing 9.9% of the class.
The position consists of 8,625,000 shares held by Fund II and the current right to acquire 3,836,101 additional shares through pre-funded warrants, limited by a 9.99% “Beneficial Ownership Limitation.” The 9.9% stake is calculated against 124,461,101 shares of Common Stock outstanding as of the filing date.
Perceptive Advisors LLC and its affiliates report beneficial ownership of 12,816,643 shares of Inhibikase Therapeutics common stock, representing 9.99% of the class. This total includes shares underlying pre-funded and common warrants held by Perceptive Life Sciences Master Fund, Ltd., subject to a 9.99% ownership cap on warrant exercise.
The ownership percentage is based on 120,899,650 shares outstanding as of a recent prospectus supplement, and reflects shared voting and dispositive power among Perceptive Advisors, Joseph Edelman, and the Master Fund. The group certifies the holdings are not for the purpose of changing or influencing control of Inhibikase.
Nantahala Capital Management, LLC and principals Wilmot B. Harkey and Daniel Mack report their beneficial ownership of Inhibikase Therapeutics common stock on an amended Schedule 13G. As of December 31, 2025, they may be deemed to beneficially own 7,037,916 shares, or 5.68% of the outstanding common stock.
This total includes 3,108,624 shares that could be acquired within sixty days through warrant exercises. The reporting persons state they share voting and dispositive power over these shares and certify the holdings are in the ordinary course of business, not for the purpose of changing or influencing control.